<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24498050</article-id><article-id pub-id-type="pmc">3907542</article-id><article-id pub-id-type="publisher-id">PONE-D-13-29222</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0087234</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Animal Models</subject><subj-group><subject>Rat</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Complementary and Alternative Medicine</subject></subj-group><subj-group><subject>Drugs and Devices</subject><subj-group><subject>Pharmacokinetics</subject><subj-group><subject>Drug Absorption</subject><subject>Drug Distribution</subject><subject>Drug Metabolism</subject></subj-group></subj-group><subj-group><subject>Drug Interactions</subject><subject>Pharmacodynamics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Veterinary Science</subject><subj-group><subject>Veterinary Pharmacology</subject></subj-group></subj-group></article-categories><title-group><article-title>Contribution of Baicalin on the Plasma Protein Binding Displacement and CYP3A Activity Inhibition to the Pharmacokinetic Changes of Nifedipine in Rats <italic>In Vivo</italic> and <italic>In Vitro</italic>
</article-title><alt-title alt-title-type="running-head">Effect of Baicalin on Metabolism of Nifedipine</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cheng</surname><given-names>Zhen-Yu</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Tian</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Hong-Meng</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Lin-Jing</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Qiao</surname><given-names>Hai-Ling</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<addr-line>Department of Clinical Pharmacology, School of Medicine, Zhengzhou University, Zhengzhou, China</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Yamanishi</surname><given-names>Yoshihiro</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Kyushu University, Japan</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>qiaohl@zzu.edu.cn</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: HLQ. Performed the experiments: ZYC XT JG HML LJJ. Analyzed the data: ZYC XT HLQ. Contributed reagents/materials/analysis tools: HLQ. Wrote the paper: ZYC XT HLQ.</p></fn></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>30</day><month>1</month><year>2014</year></pub-date><volume>9</volume><issue>1</issue><elocation-id>e87234</elocation-id><history><date date-type="received"><day>16</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>27</day><month>12</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2014 Cheng et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Cheng et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p>Baicalin purified from the root of <italic>Radix scutellariae</italic> is widely used in clinical practices. This study aimed to evaluate the effect of baicalin on the pharmacokinetics of nifedipine, a CYP3A probe substrate, in rats <italic>in vivo</italic> and <italic>in vitro</italic>. In a randomised, three-period crossover study, significant changes in the pharmacokinetics of nifedipine (2 mg/kg) were observed after treatment with a low (0.225 g/kg) or high (0.45 g/kg) dose of baicalin in rats. In the low- and high-dose groups of baicalin-treated rats, <italic>C</italic>
<sub>max</sub> of total nifedipine decreased by 40%&#x000b1;14% (<italic>P</italic>&#x0003c;0.01) and 65%&#x000b1;14% (<italic>P</italic>&#x0003c;0.01), AUC<sub>0&#x02013;&#x0221e;</sub> decreased by 41%&#x000b1;8% (<italic>P</italic>&#x0003c;0.01) and 63%&#x000b1;7% (<italic>P</italic>&#x0003c;0.01), V<sub>d</sub> increased by 85%&#x000b1;43% (<italic>P</italic>&#x0003c;0.01) and 224%&#x000b1;231% (<italic>P</italic>&#x0003c;0.01), and CL increased by 97%&#x000b1;78% (<italic>P</italic>&#x0003c;0.01) and 242%&#x000b1;135% (<italic>P</italic>&#x0003c;0.01), respectively. Plasma protein binding experiments <italic>in vivo</italic> showed that <italic>C</italic>
<sub>max</sub> of unbound nifedipine significantly increased by 25%&#x000b1;19% (<italic>P</italic>&#x0003c;0.01) and 44%&#x000b1;29% (<italic>P</italic>&#x0003c;0.01), respectively, and there was a good correlation between the unbound nifedipine (%) and baicalin concentrations (<italic>P</italic>&#x0003c;0.01). Furthermore, <italic>in vitro</italic> results revealed that baicalin was a competitive displacer of nifedipine from plasma proteins. <italic>In vitro</italic> incubation experiments demonstrated that baicalin could also competitively inhibit CYP3A activity in rat liver microsomes in a concentration-dependent manner. In conclusion, the pharmacokinetic changes of nifedipine may be modulated by the inhibitory effects of baicalin on plasma protein binding and CYP3A&#x02013;mediated metabolism.</p></abstract><funding-group><funding-statement>This work was supported by the National Natural Science Foundation of China (No. 81041113). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Plasma protein binding plays an important role in the whole-body disposition of drugs. Pharmacokinetic properties, such as distribution volume, hepatic metabolism, renal excretion and membrane transport, are highly related to the unbound fraction of drugs <xref rid="pone.0087234-Tang1" ref-type="bibr">[1]</xref>. Some studies have shown that the displacement of drugs from plasma proteins can cause significant changes in their pharmacokinetics <xref rid="pone.0087234-Lindup1" ref-type="bibr">[2]</xref>&#x02013;<xref rid="pone.0087234-Dhillon1" ref-type="bibr">[4]</xref>. Among the CYP450 enzymes, CYP3A is the most abundant isoform, which metabolises more than 50% of drugs used in clinical practices, including midazolam, nifedipine and cyclosporin A <xref rid="pone.0087234-Kazuki1" ref-type="bibr">[5]</xref>&#x02013;<xref rid="pone.0087234-Zamuner1" ref-type="bibr">[8]</xref>. Clinical and preclinical studies have reported that herbs such as <italic>Sophora flavescens</italic> and <italic>St John&#x02019;s Wort</italic> could inhibit CYP3A activity and cause herb-drug interactions <xref rid="pone.0087234-Borrelli1" ref-type="bibr">[9]</xref>, <xref rid="pone.0087234-Yang1" ref-type="bibr">[10]</xref>.</p><p>Baicalin (BA, 5, 6-Dihydroxy-flavone-7-O-glucuronide) is the principal component purified from the root of <italic>Radix scutellariae</italic> and is regarded as the marker compound for quality control of over 100 examples of compound preparations in Chinese Pharmacopoeia. Extensive studies have revealed that baicalin exhibits strong anti-oxidant <xref rid="pone.0087234-Gao1" ref-type="bibr">[11]</xref>, anti-inflammatory <xref rid="pone.0087234-Li1" ref-type="bibr">[12]</xref>, and hepato-protective <xref rid="pone.0087234-Qiao1" ref-type="bibr">[13]</xref>, <xref rid="pone.0087234-Wan1" ref-type="bibr">[14]</xref> activities. Baicalin is also a component in a wide range of vegetables, fruits, and beverages derived from plants <xref rid="pone.0087234-Uchiyama1" ref-type="bibr">[15]</xref>, <xref rid="pone.0087234-Wolniak1" ref-type="bibr">[16]</xref>. The widespread use of baicalin has led to the assessment of its safety and efficacy for human applications.</p><p>As natural vehicles for many types of endogenous and exogenous agents, plasma proteins are responsible for determining the pharmacokinetic properties of many drugs. Tang Y et al <xref rid="pone.0087234-Tang1" ref-type="bibr">[1]</xref> showed that the plasma protein binding of baicalin was within the range of 86%&#x02013;92% and the association constant (K<sub>A</sub>) was determined as 1.21&#x000d7;10<sup>5</sup> L/mol. A high protein bound drug will typically have a K<sub>A</sub> value ranging from 10<sup>5</sup> to 10<sup>7</sup> L/mol <xref rid="pone.0087234-Wright1" ref-type="bibr">[17]</xref>. Liu H et al <xref rid="pone.0087234-Liu1" ref-type="bibr">[18]</xref> reported that when administered with other Sudlow site I drugs (e.g., warfarin), baicalin could be converted into a relatively high-affinity binder of plasma albumin <italic>in vivo</italic>. Baicalin may also displace other drugs from the binding sites and enhance the potencies, which can be toxic.</p><p>Increasing attention has been paid to the effects of baicalin and other main bioactive constituents of <italic>Radix scutellariae</italic> on CYP450 enzymes. Recent studies have indicated that baicalin significantly induced CYP2B6-catalysed bupropion hydroxylation but had no effect on either CYP3A4 or MDR1 gene expression <xref rid="pone.0087234-Li2" ref-type="bibr">[19]</xref>, <xref rid="pone.0087234-Fan1" ref-type="bibr">[20]</xref>. Our preliminary studies revealed that baicalin inhibited the metabolism of dextromethorphan and midazolam, the recommended probe drugs for CYP2D and CYP3A, respectively, <italic>in vivo</italic> and <italic>in vitro</italic> in rats <xref rid="pone.0087234-Tian1" ref-type="bibr">[21]</xref>, <xref rid="pone.0087234-Tian2" ref-type="bibr">[22]</xref>. However, we found that the effects and mechanisms of baicalin on CYP2E1 were different from those of CYP2D and CYP3A; baicalin inhibited CYP2E1 <italic>in vitro</italic>, but exerted no effect on the AUC and CL of chlorzoxazone in rats <xref rid="pone.0087234-Gao2" ref-type="bibr">[23]</xref>. Importantly, the interactions observed with one CYP3A4 probe substrate may not be representative of those observed with other CYP3A4 substrates because CYP3A enzymes are known to accommodate multiple ligands in the active site. This may significantly affect the extrapolation of drug interactions from the <italic>in vitro</italic> to <italic>in vivo</italic> context or from one CYP3A4 substrate to another <italic>in vitro</italic> or <italic>in vivo</italic>
<xref rid="pone.0087234-Lamba1" ref-type="bibr">[24]</xref>, <xref rid="pone.0087234-Kenworthy1" ref-type="bibr">[25]</xref>. Thus, more than one probe drug was used to investigate drug interactions <italic>in vivo</italic>
<xref rid="pone.0087234-Zamuner2" ref-type="bibr">[26]</xref>, <xref rid="pone.0087234-Hoch1" ref-type="bibr">[27]</xref>.</p><p>Nifedipine is a typical dihydropyridine calcium channel blocker with predominant vasodilatory activity and is used widely in the treatment of hypertension and angina <xref rid="pone.0087234-Wang1" ref-type="bibr">[28]</xref>. Previous <italic>in vivo</italic> and <italic>in vitro</italic> studies have indicated that nifedipine is a representative substrate of CYP3A <xref rid="pone.0087234-Zamuner1" ref-type="bibr">[8]</xref>, <xref rid="pone.0087234-GonzalezPerez1" ref-type="bibr">[29]</xref>&#x02013;<xref rid="pone.0087234-Reilly1" ref-type="bibr">[31]</xref> and shows a different substrate behaviour compared with midazolam and testosterone <xref rid="pone.0087234-Kenworthy1" ref-type="bibr">[25]</xref>. Nifedipine binds highly to plasma proteins, and thus even small changes in protein binding are capable of producing marked changes in its pharmacokinetics <xref rid="pone.0087234-Lee1" ref-type="bibr">[32]</xref>&#x02013;<xref rid="pone.0087234-Poor1" ref-type="bibr">[34]</xref>. On the basis of these data, our study was performed to determine the effect of different doses of baicalin on the pharmacokinetics of nifedipine, and the correlation between the free fraction of nifedipine and baicalin concentrations <italic>in vivo</italic>. Moreover, we also examined the effects of baicalin on the protein binding of nifedipine and CYP3A activity <italic>in vitro</italic> to identify the underlying mechanisms of these <italic>in vivo</italic> results.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Ethics Statement</title><p>This study was performed according to the Guide for the Care and Use of Laboratory Animals. All experimental procedures reported herein were reviewed and approved by the Zhengzhou University Animal Care and Use Committee.</p></sec><sec id="s2b"><title>Drugs and Materials</title><p>Baicalin (&#x0003e;98.5% purity) was received as a gift from Henan Provincial Institute of Food and Drug Control. Nifedipine was purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). NADPH was obtained from Roche Co. Ltd. (Switzerland). Diazepam injections were purchased from Tianjin Jin Yao Amino Acid Co., Ltd. (China). Ultrafiltration tubes (0.5 ml, 10KD) were purchased from Millipore (USA). All organic solvents of HPLC purity were obtained from Siyou Chemical Reagent Co. (Tianjin, China).</p></sec><sec id="s2c"><title>Animals</title><p>Male Sprague Dawley rats (200&#x02013;250 g) were obtained from the Laboratory Animal Center of Henan Province (Henan, China). Rats were housed in a temperature-controlled colony room under a 12 h light/dark cycle and had free access to food and water for 1 week prior to experiments. Rats were fasted overnight prior to the experiment, and given free access to water.</p></sec><sec id="s2d"><title>Pharmacokinetic Studies of Nifedipine</title><p>The baicalin solution for the injections was prepared by dissolving 250 mg baicalin in 50 ml of Na<sub>2</sub>HPO<sub>4</sub> (0.2 M) and adjusting to pH 7.4 with citric acid (0.1 M). The nifedipine solution for the injections were prepared by dissolving 20 mg of nifedipine in a mixture of polyethylene glycol 400 (5 ml) and saline (10 ml) according to Mohri K et al <xref rid="pone.0087234-Mohri1" ref-type="bibr">[35]</xref> with slight modifications.</p><p>Twelve rats were randomly divided into 3 groups (n&#x0200a;=&#x0200a;4, each group), and the order of the baicalin doses was administered according to a Latin-Square design (saline, 0.225 and 0.45 g/kg) with a 3-day wash-out period between treatments. All pharmacokinetic data were obtained from 12 animals. In the pharmacokinetic studies, the rats were treated either with saline, low (0.225 g/kg) or high (0.45 g/kg) doses of baicalin. Nifedipine was administered immediately following the injection of baicalin or saline via the tail vein. In the pharmacokinetic studies, blood samples (300 &#x000b5;l) for pharmacokinetic analyses were collected pre-dose and at 0, 0.167, 0.5, 1, 2, 3 and 4 h post-nifedipine dose by orbital bleeding via heparinised capillary tubes. The plasma was obtained by centrifugation at 4,500 rpm for 10 min at 4&#x000b0;C and frozen at &#x02212;80&#x000b0;C prior to analysis.</p></sec><sec id="s2e"><title>HPLC Analysis of Nifedipine and Baicalin</title><p>The concentration of nifedipine in the blood samples was determined by a slight modification of a previously reported high-performance liquid chromatography (HPLC) method with gradient elution (63%&#x02013;90% methanol in water) and UV detection at 235 nm <xref rid="pone.0087234-Guo1" ref-type="bibr">[36]</xref>. Briefly, 10 &#x000b5;l of diazepam (0.09 mg/ml) as internal standard was added to a blood sample, which was then alkalinised by 15 &#x000b5;l of ammonia and subjected to liquid&#x02013;liquid extraction using 2 ml ether. After vortex mixing for 2 min and centrifuging at 3,000 rpm for 10 min, 1.6 ml of the organic phase was transferred into another glass centrifuge tube and evaporated to dryness at 40&#x000b0;C under a gentle stream of nitrogen. The residue was reconstituted with 100 &#x000b5;l of mobile phase, and 40 &#x000b5;l was injected into the HPLC system (Agilent 1100 Series) for analysis. The quantitation limits of nifedipine in the rat plasma samples were 0.20 mg/L. All operations were performed under weak red light.</p><p>The concentration of baicalin in the blood samples was determined using a slightly modified high-performance liquid chromatography (HPLC) protocol with UV detection at 278 nm <xref rid="pone.0087234-Zeng1" ref-type="bibr">[37]</xref>. Briefly, 100 &#x000b5;l methanol was added to 25 &#x000b5;l of the blood sample. The mixture was vortex for 1 min after which it was centrifuged at 15,000 rpm for 10 min at 4&#x000b0;C, and 5 &#x000b5;l supernatant was then injected into the HPLC system (Agilent 1100 Series) for analysis. The quantitation limits of baicalin in the rat plasma were 5.86 mg/L.</p></sec><sec id="s2f"><title>Plasma Protein Binding of Nifedipine <italic>in vivo</italic> and <italic>in vitro</italic>
</title><p>For the <italic>in vivo</italic> study, the protein-binding of nifedipine in plasma at different sampling times after treatment with baicalin (0.225, 0.45 g/kg, iv) were evaluated using ultrafiltration. Plasma samples containing nifedipine and baicalin were prepared <italic>in vitro</italic>. The concentrations of nifedipine were from 13.0 to 52.0 mg/L, and the concentrations of baicalin were from 0 to 2000.0 mg/L. The resulting mixture was subsequently incubated at 37&#x000b0;C for 30 min, and 0.2 ml aliquots were placed into an ultrafiltration device (Millipore, USA). After centrifuging at 2,000 rpm for 20 min, concentrations of nifedipine were measured using HPLC.</p></sec><sec id="s2g"><title>Effects of baicalin on CYP3A Activity <italic>in vitro</italic>
</title><p>The preparation of rat liver microsome (RLM) suspensions were performed as previously reported <xref rid="pone.0087234-Litterst1" ref-type="bibr">[38]</xref>. The effect of baicalin on CYP3A activity was evaluated by measuring the metabolic velocity of nifedipine in RLMs. Briefly, the incubation mixtures (total volume 0.2 ml) contained microsomal protein (0.25 mg/ml), phosphate buffer (100 mM, pH 7.4), MgCl<sub>2</sub> (3 mM), NADPH (1 mM), EDTA (0.1 mM), nifedipine (9.38&#x02013;150 &#x000b5;M) and baicalin (12.5&#x02013;200 &#x000b5;M). The reaction time was 30 min with a pre-incubation of 5 min without the addition of NADPH and was terminated by adding acetonitrile (20 &#x000b5;l). The mixture was vortex for 1 min after which it was centrifuged at 15,000 rpm for 10 min, and 20 &#x000b5;l supernatant was then injected into the HPLC system for analysis. The kinetic constants (K<sub>m</sub> and V<sub>max</sub>) for the disappearance of nifedipine and inhibition constants (K<sub>i</sub>) were calculated using the nonlinear regression method. The quantitation limits of nifedipine in the RLM samples were 2.34 &#x000b5;mol/L.</p></sec><sec id="s2h"><title>Data Analysis</title><p>The pharmacokinetic parameters were determined using a non-compartmental pharmacokinetic model with the DAS 2.0 package (version 2.0 pharmacokinetic software; Chinese Pharmacological Assn., Beijing, China). Michaelis-Menten Enzyme kinetics data were fitted using non-linear regression analysis with GraphPad Prism 5 (GraphPad Software Inc., CA, USA). The mechanism of inhibition was determined by visual inspection of the data using a Lineweaver-Burke (1/[S] vs. 1/v) plot. The K<sub>i</sub> was obtained using the secondary plot of the Lineweaver-Burk plot. The peak plasma concentration of the total and unbound nifedipine was obtained from actual data (t&#x0200a;=&#x0200a;0 h). The data of <italic>C</italic>
<sub>max</sub>, AUC and CL were analysed using the paired <italic>t</italic>-test. Correlations were measured using Pearson's correlation coefficient and Spearman's Rho. The results are expressed as the mean &#x000b1; SD. A value of <italic>P</italic>&#x0003c;0.05 was considered to be statistically significant. All statistical analyses were performed with <italic>SPSS</italic> 17.0 for Windows.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Effects of baicalin on the Pharmacokinetics of nifedipine in Rats</title><sec id="s3a1"><title>The pharmacokinetics of nifedipine in rats</title><p>The mean plasma concentration&#x02013;time profiles of total nifedipine after the intravenous administration of nifedipine (2 mg/kg, i.v.) with saline (control) or baicalin (0.225, 0.45 g/kg) are shown in <xref ref-type="fig" rid="pone-0087234-g001">Figure 1</xref>. The key pharmacokinetic parameters of nifedipine are summarised in <xref ref-type="table" rid="pone-0087234-t001">Table 1</xref>. These results showed that after treatment with baicalin (0.225, 0.45 g/kg), the maximum concentrations (<italic>C</italic>
<sub>max</sub>) of total nifedipine decreased by 40%&#x000b1;14% and 65%&#x000b1;14% (<italic>P</italic>&#x0003c;0.01), area under plasma concentration&#x02013;time curve (AUC<sub>0&#x02013;&#x0221e;</sub>) decreased by 41%&#x000b1;8% and 63%&#x000b1;7% (<italic>P</italic>&#x0003c;0.01), apparent volume of distribution (V<sub>d</sub>) increased by 85% &#x000b1;43% and 224%&#x000b1;231% (<italic>P</italic>&#x0003c;0.01), and clearance (CL) increased by 97%&#x000b1;78% and 242%&#x000b1;135% (<italic>P</italic>&#x0003c;0.01). These observations strongly indicated that baicalin significantly altered the pharmacokinetics of nifedipine in rats.</p><fig id="pone-0087234-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087234.g001</object-id><label>Figure 1</label><caption><title>The plasma concentration-time profiles of total nifedipine (2 mg/kg, i.v.) after treatment with baicalin (0.225, 0.45 g/kg) in rats (mean &#x000b1; SD, n&#x0200a;=&#x0200a;12).</title></caption><graphic xlink:href="pone.0087234.g001"/></fig><table-wrap id="pone-0087234-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087234.t001</object-id><label>Table 1</label><caption><title>Pharmacokinetics parameters of nifedipine (2 mg/kg, i.v.) after treatment with baicalin (0.225, 0.45 g/kg, i.v.) in rats (n&#x0200a;=&#x0200a;12).</title></caption><alternatives><graphic id="pone-0087234-t001-1" xlink:href="pone.0087234.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td colspan="2" align="left" rowspan="1">Baicalin (0.225 g/kg)</td><td colspan="2" align="left" rowspan="1">Baicalin (0.45 g/kg)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Value</td><td align="left" rowspan="1" colspan="1">Value</td><td align="left" rowspan="1" colspan="1">Ratio</td><td align="left" rowspan="1" colspan="1">Value</td><td align="left" rowspan="1" colspan="1">Ratio</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>C</italic>
<sub>max</sub> (mg/L)</td><td align="left" rowspan="1" colspan="1">14.12&#x000b1;2.70</td><td align="left" rowspan="1" colspan="1">8.42&#x000b1;2.28<xref ref-type="table-fn" rid="nt103">**</xref>
</td><td align="left" rowspan="1" colspan="1">0.60&#x000b1;0.14</td><td align="left" rowspan="1" colspan="1">4.97&#x000b1;1.75<xref ref-type="table-fn" rid="nt103">**</xref>
<sup>&#x025b3;&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">0.35&#x000b1;0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">T<sub>1/2</sub>(h)</td><td align="left" rowspan="1" colspan="1">0.40&#x000b1;0.17</td><td align="left" rowspan="1" colspan="1">0.26&#x000b1;0.07</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.46&#x000b1;0.22</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">V(L/kg)</td><td align="left" rowspan="1" colspan="1">0.14&#x000b1;0.03</td><td align="left" rowspan="1" colspan="1">0.26&#x000b1;0.06<xref ref-type="table-fn" rid="nt103">**</xref>
</td><td align="left" rowspan="1" colspan="1">1.85&#x000b1;0.43</td><td align="left" rowspan="1" colspan="1">0.46&#x000b1;0.07<xref ref-type="table-fn" rid="nt103">**</xref>
<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">3.24&#x000b1;2.31</td></tr><tr><td align="left" rowspan="1" colspan="1">CL(L/h/kg)</td><td align="left" rowspan="1" colspan="1">0.27&#x000b1;0.07</td><td align="left" rowspan="1" colspan="1">0.54&#x000b1;0.12<xref ref-type="table-fn" rid="nt103">**</xref>
</td><td align="left" rowspan="1" colspan="1">1.97&#x000b1;0.78</td><td align="left" rowspan="1" colspan="1">0.94&#x000b1;0.34<xref ref-type="table-fn" rid="nt103">**</xref>
<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">3.42&#x000b1;1.35</td></tr><tr><td align="left" rowspan="1" colspan="1">AUC<sub>0&#x02013;t</sub>(mg&#x000b7;h/L)</td><td align="left" rowspan="1" colspan="1">10.43&#x000b1;1.35</td><td align="left" rowspan="1" colspan="1">5.87&#x000b1;1.10<xref ref-type="table-fn" rid="nt103">**</xref>
</td><td align="left" rowspan="1" colspan="1">0.57&#x000b1;0.09</td><td align="left" rowspan="1" colspan="1">3.66&#x000b1;0.63<xref ref-type="table-fn" rid="nt103">**</xref>
<sup>&#x025b3;&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">0.35&#x000b1;0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">AUC<sub>0&#x02013;&#x0221e;</sub>(mg&#x000b7;h/L)</td><td align="left" rowspan="1" colspan="1">11.14&#x000b1;1.17</td><td align="left" rowspan="1" colspan="1">6.58&#x000b1;1.29<xref ref-type="table-fn" rid="nt103">**</xref>
</td><td align="left" rowspan="1" colspan="1">0.59&#x000b1;0.08</td><td align="left" rowspan="1" colspan="1">4.06&#x000b1;0.67<xref ref-type="table-fn" rid="nt103">**</xref>
</td><td align="left" rowspan="1" colspan="1">0.37&#x000b1;0.07</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>vs. control,</p></fn><fn id="nt102"><label>*</label><p>
<italic>P</italic>&#x0003c;0.05,</p></fn><fn id="nt103"><label>**</label><p>
<italic>P</italic>&#x0003c;0.01.</p></fn><fn id="nt104"><label/><p>vs. baicalin (0.225 g/kg, i.v.),</p></fn><fn id="nt105"><label>&#x025b3;</label><p>
<italic>P</italic>&#x0003c;0.05,</p></fn><fn id="nt106"><label>&#x025b3;&#x025b3;</label><p>
<italic>P</italic>&#x0003c;0.01.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3a2"><title>Individual variability of nifedipine pharmacokinetic changes</title><p>As shown in <xref ref-type="fig" rid="pone-0087234-g002">Figure 2A</xref>, a significant decrease in <italic>C</italic>
<sub>max</sub> of nifedipine occurred after treatment with baicalin. However, the <italic>C</italic>
<sub>max</sub> of rat 7 decreased by 12.11%, while that of rat 8 decreased by 57.91% when the rats received baicalin at a dose of 0.225 g/kg. Moreover, there was a nearly 3-fold difference in <italic>C</italic>
<sub>max</sub> at a dose of 0.45 g/kg. In addition, corresponding AUC<sub>0&#x02013;&#x0221e;</sub>, V<sub>d</sub> and CL variations were also observed (<xref ref-type="fig" rid="pone-0087234-g002">Figure 2B, C and D</xref>). Taken together, the data showed that there were large inter-individual differences in the nifedipine-baicalin interactions.</p><fig id="pone-0087234-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087234.g002</object-id><label>Figure 2</label><caption><title>The inter-individual differences in the changes induced by baicalin (0.225, 0.45 g/kg) in the pharmacokinetic parameters of nifedipine (2 mg/kg) (mean &#x000b1; SD, n&#x0200a;=&#x0200a;12).</title></caption><graphic xlink:href="pone.0087234.g002"/></fig></sec><sec id="s3a3"><title>Relationship between the concentration changes of nifedipine and the concentrations of baicalin</title><p>The pharmacokinetic parameters of baicalin at doses of 0.225 and 0.45 g/kg were examined (data not shown). We discovered that there were significant correlations except in two rats treated with baicalin at 0.225 g/kg and another two rats treated with baicalin at 0.45 g/kg (<xref ref-type="fig" rid="pone-0087234-g003">Figure 3A and C</xref>). The correlations between the mean changes in nifedipine concentrations and mean baicalin concentrations in rats are shown in <xref ref-type="fig" rid="pone-0087234-g003">Figure 3B and 3D</xref>. The coefficients (r) were 0.9911 and 0.9973, respectively.</p><fig id="pone-0087234-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087234.g003</object-id><label>Figure 3</label><caption><title>Relationship between changes in nifedipine concentrations and corresponding baicalin concentrations in rats.</title><p>(A), (C) Correlation coefficient of changes in nifedipine concentration in different sampling times and corresponding baicalin concentrations in rats. (B) (D) Plots of the mean changes in nifedipine concentrations in rats treated with baicalin (0.225, 0.45 g/kg) versus mean baicalin concentrations of corresponding doses (n&#x0200a;=&#x0200a;12). *<italic>P</italic>&#x0003e;0.05 in correlation analysis.</p></caption><graphic xlink:href="pone.0087234.g003"/></fig></sec></sec><sec id="s3b"><title>Plasma Protein Binding of nifedipine <italic>in vivo</italic> and <italic>in vitro</italic>
</title><p>To examine the interaction between baicalin and nifedipine <italic>in vivo</italic>, we examined the unbound fraction of nifedipine at the sampling time 0, 0.167, 0.5 and 1 h. As shown in <xref ref-type="fig" rid="pone-0087234-g004">Figure 4A</xref>, the results showed that the <italic>C</italic>
<sub>max</sub> of unbound nifedipine was significantly increased by 25%&#x000b1;19% and 44%&#x000b1;29% (<italic>P</italic>&#x0003c;0.01), respectively. An <italic>in vivo</italic> protein binding study also revealed detailed changes of unbound nifedipine (%) in the pharmacokinetic samples for nifedipine when treated with saline or baicalin. The unbound nifedipine (%) values after treatment with baicalin (0.225, 0.45 g/kg) were 8.09% and 16.06% at 0 h, and the mean unbound nifedipine (%) after treatment with nifedipine and saline was 3.92%.</p><fig id="pone-0087234-g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087234.g004</object-id><label>Figure 4</label><caption><title>Interaction of nifedipine and baicalin for plasma proteins <italic>in vivo</italic> and <italic>in vitro</italic>.</title><p>(A) The plasma concentration-time profiles of unbound nifedipine (2 mg/kg, i.v.) after treatment with baicalin (0.225, 0.45 g/kg) in rats. (B) Correlation between unbound nifedipine (%) and corresponding baicalin concentrations in rats. (C) Double reciprocal plot of the molar concentration of unbound versus bound nifedipine in plasma. The plasma nifedipine concentration ranged from 13 to 52 mg/L.</p></caption><graphic xlink:href="pone.0087234.g004"/></fig><p>A positive rank order correlation between unbound nifedipine (%) and corresponding baicalin concentrations in rats (r&#x0200a;=&#x0200a;0.8651) is shown in <xref ref-type="fig" rid="pone-0087234-g004">Figure 4B</xref>. These results demonstrated a good prediction of unbound nifedipine (%) from the baicalin concentration value.</p><p>The present assay has been successfully applied to quantify the concentration of nifedipine in rat plasma in drug&#x02013;protein binding studies in the presence or absence of baicalin using ultrafiltration <italic>in vivo</italic> and <italic>in vitro</italic>. The double reciprocal plot for unbound nifedipine concentrations (%) to plasma protein in the absence and presence of baicalin at concentrations of 250, 500, 1000, 2000 mg/L is shown in <xref ref-type="fig" rid="pone-0087234-g004">Figure 4C</xref>. These results clearly illustrated that the interactions between nifedipine and baicalin for rat plasma proteins were competitive, and the unbound nifedipine (%) significantly increased from 4.00% to 8.28% with increasing concentrations of baicalin.</p></sec><sec id="s3c"><title>Effects of baicalin on CYP3A Activity</title><p>To investigate the kinetics of the inhibitory effects of baicalin on hepatic CYP3A activity, nifedipine disappearance in RLMs was examined in the presence and absence of baicalin <italic>in vitro</italic>. In the absence of baicalin, the K<sub>m</sub>, V<sub>max</sub>, and CL<sub>int</sub> of nifedipine in RLMs were 24.25 &#x000b5;M, 8.04 nmol/min/mg protein and 0.33 ml/min/mg protein, respectively. An inhibition study was performed at various concentrations of baicalin (<xref ref-type="fig" rid="pone-0087234-g005">Figure 5</xref>). The intersection point of these lines corresponds to each baicalin concentration and was close to the y-axis (<xref ref-type="fig" rid="pone-0087234-g005">Figure 5A</xref>). It has been suggested that the inhibition of CYP3A by baicalin was best fit in a competitive manner. The K<sub>i</sub> value was calculated from second plot of the slopes derived from the Lineweaver-Burk plots vs. the concentrations of baicalin and was 145.5 &#x000b5;M (64.9 mg/L) (<xref ref-type="fig" rid="pone-0087234-g005">Figure 5B</xref>).</p><fig id="pone-0087234-g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087234.g005</object-id><label>Figure 5</label><caption><title>Effects of baicalin on CYP3A activity <italic>in vitro</italic>.</title><p>(A) Primary Lineweaver-Burke plots were used to plot the effect of baicalin on nifedipine metabolism in RLMs. (B) Secondary plots of rat CYP3A activity using the slopes of primary Lineweaver-Burke plots versus the concentration of baicalin.</p></caption><graphic xlink:href="pone.0087234.g005"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p>In recent years, there has been growing interest in herb-drug interactions, as they can potentially cause toxicity and/or attenuate drug efficacy in clinical treatment. Baicalin, as a marker compound for many herb medicines, is a high protein bound drug and inhibitor of CYP450s <xref rid="pone.0087234-Liu1" ref-type="bibr">[18]</xref>, <xref rid="pone.0087234-Gao2" ref-type="bibr">[23]</xref>. It has been speculated that the herb-drug interaction may occur when baicalin is co-administered with other drugs.</p><p>Nifedipine, a substrate of CYP3A with high protein binding <xref rid="pone.0087234-SchmiedlinRen1" ref-type="bibr">[39]</xref>, <xref rid="pone.0087234-Kim1" ref-type="bibr">[40]</xref>, is widely used in the treatment of hypertension and angina. Hypertensive patients require long-term health care, and nifedipine is commonly co-administered with other drugs, such as baicalin. The interaction between baicalin and nifedipine was performed in this study to investigate the effects of baicalin on pharmacokinetics <italic>in vivo</italic> and metabolism in an <italic>in vitro</italic> incubation system of nifedipine.</p><p>After the intravenous co-administration of nifedipine and baicalin (0.225, 0.45 g/kg), the mean values of AUC of nifedipine were significantly lower compared to treatment without baicalin by approximately 41% and 63%, respectively. The mean values of CL were significantly enhanced by approximately 97% and 242%, respectively. These data showed that co-administration of baicalin markedly contributed to the changes in the pharmacokinetics of nifedipine.</p><p>The V<sub>d</sub> and CL of drugs with high plasma protein binding capacity, such as nifedipine, were affected by other drugs <xref rid="pone.0087234-Dhillon1" ref-type="bibr">[4]</xref>, <xref rid="pone.0087234-Buur1" ref-type="bibr">[41]</xref>. Because both nifedipine and baicalin are highly bound to plasma proteins, it is conceivable that baicalin could displace nifedipine from binding sites, resulting in changes in the pharmacokinetics of nifedipine. The displaced nifedipine from the plasma protein sites would then redistribute to the extravascular space with an increase in V<sub>d</sub> and decrease in <italic>C</italic>
<sub>max</sub> of total nifedipine. The unbound fraction of nifedipine was increased despite the significant decrease in total nifedipine after baicalin treatment (<xref ref-type="fig" rid="pone-0087234-g004">Figure 4A</xref>). Interestingly, the unbound nifedipine (%) in rats treated with baicalin (0.225, 0.45 g/kg) was increased nearly four times more than that of control, varying from 3.92% to 16.06%. This type of displacement has been demonstrated in our previous study where baicalin, as a potential displacer for plasma protein binding sites, exhibited significantly increased unbound chlorzoxazone concentrations <italic>in vivo</italic> in rats <xref rid="pone.0087234-Gao2" ref-type="bibr">[23]</xref>. The intrinsic clearance (CL<sub>int</sub>) was calculated from CL<sub>total</sub>/f<sub>u</sub>, where f<sub>u</sub> is the unbound-fraction of nifedipine in plasma, and CL<sub>int</sub> is directly related to the activities of the enzymes, which remove drugs from the body <xref rid="pone.0087234-Choi1" ref-type="bibr">[42]</xref>. Thus, the increase in CL<sub>total</sub> is due to the increase in the unbound fraction of nifedipine. Furthermore, an <italic>in vivo</italic> protein binding study also showed that there was a good correlation between unbound nifedipine (%) and corresponding baicalin concentrations in rats (r&#x0200a;=&#x0200a;0.8651) after treatment with baicalin. This finding demonstrated a good prediction of the baicalin effect on unbound nifedipine (%) from the baicalin plasma concentration value. Moreover, there was no change in nifedipine T<sub>1/2</sub> associated with baicalin administration, potentially because the T<sub>1/2</sub> in a two compartment system is a &#x02018;hybrid&#x02019; parameter that reflects drug clearance and the apparent volume of distribution <xref rid="pone.0087234-Lombardo1" ref-type="bibr">[43]</xref>. In this study, baicalin not only inhibited CYP3A, but it also significantly increased the unbound concentration and decreased the AUC of nifedipine in rats. These results differed from the inhibitory effects of baicalin on other CYPs in our previous studies <xref rid="pone.0087234-Tian1" ref-type="bibr">[21]</xref>&#x02013;<xref rid="pone.0087234-Gao2" ref-type="bibr">[23]</xref>, suggesting that baicalin confers multiple effects on the activities of different CYPs and the pharmacokinetics of probe drugs via various mechanisms.</p><p>To determine if the interactions between baicalin and nifedipine in these cases resulted from a competition for plasma proteins, an <italic>in vitro</italic> protein binding study was performed. We discovered that baicalin competitively displaces nifedipine from plasma protein binding sites as demonstrated by the change in slope of the double reciprocal plot (<xref ref-type="fig" rid="pone-0087234-g004">Figure 4C</xref>) obtained from the <italic>in vitro</italic> plasma protein binding experiment <xref rid="pone.0087234-Soligard1" ref-type="bibr">[44]</xref>. The <italic>C</italic>
<sub>max</sub> values of baicalin in rats treated with baicalin (0.225, 0.45 g/kg) were 754.8 mg/L and 1,280.4 mg/L, respectively, and when the concentration of baicalin was increased above 250 mg/L, the unbound nifedipine significantly increased in the <italic>in vitro</italic> study (<xref ref-type="fig" rid="pone-0087234-g004">Figure 4C</xref>).</p><p>The current study assessed the inter-individual variations in drug distribution and metabolism using a self-controlled rat model (<xref ref-type="fig" rid="pone-0087234-g003">Figure 3</xref>). We observed the increase in V<sub>d</sub>, which ranged from 25% to 765% and in CL, which ranged from 50% to 513%. These results indicated that there was a large difference in the effects of baicalin on the metabolism of nifedipine in rats. Furthermore, it is well known that inter-individual differences in pharmacokinetics are much greater in humans compared to experimental animals <xref rid="pone.0087234-Iwatsubo1" ref-type="bibr">[45]</xref>. Nifedipine is a drug that shows extremely broad inter-individual metabolic differences in human <xref rid="pone.0087234-Renwick1" ref-type="bibr">[46]</xref>, <xref rid="pone.0087234-Miyazaki1" ref-type="bibr">[47]</xref>. Thus, additional studies are warranted to examine the interaction between baicalin and nifedipine in clinical practices.</p><p>Baicalin has been shown to inhibit the CYP3A-mediated metabolism of midazolam and cyclosporine <italic>in vivo</italic>
<xref rid="pone.0087234-Tian2" ref-type="bibr">[22]</xref>, <xref rid="pone.0087234-Lai1" ref-type="bibr">[48]</xref>. However, in the present study, baicalin did not demonstrate a direct inhibition on the pharmacokinetics of nifedipine. To explore whether baicalin can inhibit the metabolism of nifedipine, an <italic>in vitro</italic> incubation study in RLMs was performed in a subsequent study. These findings showed that the K<sub>m</sub> and V<sub>max</sub> values were consistent with previous observations <xref rid="pone.0087234-Aoki1" ref-type="bibr">[49]</xref>, and baicalin was a relatively weak inhibitor of CYP3A in RLMs, with a competitive inhibitory effect. However, the pharmacokinetics of baicalin studies showed that the <italic>C</italic>
<sub>max</sub> values of baicalin in rats treated with baicalin at 0.225 g/kg and 0.45 g/kg were 754.8 mg/L and 1280.4 mg/L, respectively. Nifedipine is a low extraction drug with ER ranges from 0.22 to 0.32 <xref rid="pone.0087234-Grundy1" ref-type="bibr">[50]</xref>. For low hepatic extraction ratio drugs, the magnitude of an <italic>in vivo</italic> drug&#x02013;drug interaction obtained from the inhibition of metabolic clearance can be predicted using the ratio of the inhibitor concentration ([I]) to inhibition constant (K<sub>i</sub>) <xref rid="pone.0087234-Ito1" ref-type="bibr">[51]</xref>. In this study, K<sub>i</sub> was dramatically lower than [I]; thus, the effect of baicalin on nifedipine was noticeable. It is also well known that an increase in the unbound fraction of a drug by a displacer will increase its clearance based on the total plasma drug concentration, which in turn, may mask a concomitant effect of the displacer as an enzyme inhibitor in decreasing drug clearance <xref rid="pone.0087234-Christensen1" ref-type="bibr">[52]</xref>, <xref rid="pone.0087234-Lilja1" ref-type="bibr">[53]</xref>. It has been speculated that the higher unbound concentrations might be sustained for the duration of baicalin therapy and cause lethargy, bradycardia, marked hypotension and a loss of consciousness in humans [54]. In summary, the significant change in the pharmacokinetics of nifedipine in baicalin-treated rats is due to the combined inhibitory activity of CYP3A and the displacement of nifedipine from plasma protein binding sites by baicalin.</p><p>In the present study, an increase in the unbound concentration and decrease in AUC of nifedipine in plasma were observed after co-administration of baicalin in rats. The higher unbound concentrations might be sustained for the duration of baicalin therapy because baicalin also decreased the intrinsic clearance of nifedipine <italic>in vitro</italic>. If the results could be extrapolated to humans, then modification of the regimens of nifedipine and baicalin might be required and appropriate strategies should be adopted to minimise the adverse drug reactions in clinical practices. However, the baicalin-nifedipine interaction requires further investigations in human due to species differences between rat and human.</p></sec></body><back><ref-list><title>References</title><ref id="pone.0087234-Tang1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Tang</surname><given-names>Y</given-names></name>, <name><surname>Zhu</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Huang</surname><given-names>C</given-names></name> (<year>2006</year>) <article-title>Determination of human plasma protein binding of baicalin by ultrafiltration and high-performance liquid chromatography</article-title>. <source>Biomedical Chromatography</source>
<volume>20</volume>: <fpage>1116</fpage>&#x02013;<lpage>1119</lpage>.<pub-id pub-id-type="pmid">16708379</pub-id></mixed-citation></ref><ref id="pone.0087234-Lindup1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Lindup</surname><given-names>WE</given-names></name>, <name><surname>Orme</surname><given-names>MC</given-names></name> (<year>1981</year>) <article-title>Clinical pharmacology: plasma protein binding of drugs</article-title>. <source>British Medical Journal (Clinical Research Edition)</source>
<volume>282</volume>: <fpage>212</fpage>&#x02013;<lpage>214</lpage>.</mixed-citation></ref><ref id="pone.0087234-Addison1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Addison</surname><given-names>RS</given-names></name>, <name><surname>Parker-Scott</surname><given-names>SL</given-names></name>, <name><surname>Eadie</surname><given-names>MJ</given-names></name>, <name><surname>Hooper</surname><given-names>WD</given-names></name>, <name><surname>Dickinson</surname><given-names>RG</given-names></name> (<year>2000</year>) <article-title>Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers</article-title>. <source>European Journal of Clinical Pharmacology</source>
<volume>56</volume>: <fpage>715</fpage>&#x02013;<lpage>721</lpage>.<pub-id pub-id-type="pmid">11214782</pub-id></mixed-citation></ref><ref id="pone.0087234-Dhillon1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Dhillon</surname><given-names>S</given-names></name>, <name><surname>Richens</surname><given-names>A</given-names></name> (<year>1998</year>) <article-title>Valproic acid and diazepam interaction <italic>in vivo</italic>
</article-title>. <source>British Journal of Clinical Pharmacology</source>
<volume>13</volume>: <fpage>553</fpage>&#x02013;<lpage>560</lpage>.</mixed-citation></ref><ref id="pone.0087234-Kazuki1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Kazuki</surname><given-names>Y</given-names></name>, <name><surname>Kobayashi</surname><given-names>K</given-names></name>, <name><surname>Aueviriyavit</surname><given-names>S</given-names></name>, <name><surname>Oshima</surname><given-names>T</given-names></name>, <name><surname>Kuroiwa</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans</article-title>. <source>Human Molecular Genetics</source>
<volume>22</volume>: <fpage>578</fpage>&#x02013;<lpage>592</lpage>.<pub-id pub-id-type="pmid">23125282</pub-id></mixed-citation></ref><ref id="pone.0087234-Lehr1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Lehr</surname><given-names>T</given-names></name>, <name><surname>Staab</surname><given-names>A</given-names></name>, <name><surname>Trommeshauser</surname><given-names>D</given-names></name>, <name><surname>Schaefer</surname><given-names>HG</given-names></name>, <name><surname>Kloft</surname><given-names>C</given-names></name> (<year>2010</year>) <article-title>Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole</article-title>. <source>Clinical Pharmacokinetics</source>
<volume>49</volume>: <fpage>53</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">20000889</pub-id></mixed-citation></ref><ref id="pone.0087234-deJonge1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>de Jonge</surname><given-names>H</given-names></name>, <name><surname>de Loor</surname><given-names>H</given-names></name>, <name><surname>Verbeke</surname><given-names>K</given-names></name>, <name><surname>Vanrenterghem</surname><given-names>Y</given-names></name>, <name><surname>Kuypers</surname><given-names>DR</given-names></name> (<year>2011</year>) <article-title>
<italic>In vivo</italic> CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients</article-title>. <source>Clinical Pharmacology and Therapeutics</source>
<volume>90</volume>: <fpage>414</fpage>&#x02013;<lpage>422</lpage>.<pub-id pub-id-type="pmid">21753749</pub-id></mixed-citation></ref><ref id="pone.0087234-Zamuner1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Zamuner</surname><given-names>S</given-names></name>, <name><surname>Johnson</surname><given-names>BM</given-names></name>, <name><surname>Pagliarusco</surname><given-names>S</given-names></name>, <name><surname>Fina</surname><given-names>P</given-names></name>, <name><surname>Peroni</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine</article-title>. <source>British Journal of Clinical Pharmacology</source>
<volume>70</volume>: <fpage>537</fpage>&#x02013;<lpage>546</lpage>.<pub-id pub-id-type="pmid">20840445</pub-id></mixed-citation></ref><ref id="pone.0087234-Borrelli1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Borrelli</surname><given-names>F</given-names></name>, <name><surname>Izzo</surname><given-names>AA</given-names></name> (<year>2009</year>) <article-title>Herb-drug interactions with <italic>St John's wort</italic> (Hypericum perforatum): an update on clinical observations</article-title>. <source>The AAPS Journal</source>
<volume>11</volume>: <fpage>710</fpage>&#x02013;<lpage>727</lpage>.<pub-id pub-id-type="pmid">19859815</pub-id></mixed-citation></ref><ref id="pone.0087234-Yang1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Yang</surname><given-names>JM</given-names></name>, <name><surname>Ip</surname><given-names>SP</given-names></name>, <name><surname>Xian</surname><given-names>Y</given-names></name>, <name><surname>Zhao</surname><given-names>M</given-names></name>, <name><surname>Lin</surname><given-names>ZX</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Impact of the herbal medicine <italic>Sophora flavescens</italic> on the oral pharmacokinetics of indinavir in rats: the involvement of CYP3A and P-glycoprotein</article-title>. <source>PloS One</source>
<volume>7</volume>: <fpage>e31312</fpage>.<pub-id pub-id-type="pmid">22359586</pub-id></mixed-citation></ref><ref id="pone.0087234-Gao1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Gao</surname><given-names>Z</given-names></name>, <name><surname>Huang</surname><given-names>K</given-names></name>, <name><surname>Xu</surname><given-names>H</given-names></name> (<year>2001</year>) <article-title>Protective effects of flavonoids in the roots of <italic>Scutellaria baicalensis Georgi</italic> against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells</article-title>. <source>Pharmacological research</source>
<volume>43</volume>: <fpage>173</fpage>&#x02013;<lpage>178</lpage>.<pub-id pub-id-type="pmid">11243719</pub-id></mixed-citation></ref><ref id="pone.0087234-Li1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Bao</surname><given-names>H</given-names></name>, <name><surname>Wu</surname><given-names>J</given-names></name>, <name><surname>Duan</surname><given-names>X</given-names></name>, <name><surname>Liu</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Baicalin is anti-inflammatory in cigarette smoke-induced inflammatory models <italic>in vivo</italic> and <italic>in vitro</italic>: A possible role for HDAC2 activity</article-title>. <source>International Immunopharmacology</source>
<volume>13</volume>: <fpage>15</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">22421405</pub-id></mixed-citation></ref><ref id="pone.0087234-Qiao1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Qiao</surname><given-names>H</given-names></name>, <name><surname>Han</surname><given-names>H</given-names></name>, <name><surname>Hong</surname><given-names>D</given-names></name>, <name><surname>Ren</surname><given-names>Z</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Protective effects of baicalin on carbon tetrachloride induced liver injury by activating PPAR&#x003b3; and inhibiting TGF&#x003b2;1</article-title>. <source>Pharmaceutical Biology</source>
<volume>49</volume>: <fpage>38</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">20687787</pub-id></mixed-citation></ref><ref id="pone.0087234-Wan1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Wan</surname><given-names>JY</given-names></name>, <name><surname>Gong</surname><given-names>X</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Li</surname><given-names>HZ</given-names></name>, <name><surname>Zhou</surname><given-names>YF</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Protective effect of baicalin against lipopolysaccharide/D-galactosamine-induced liver injury in mice by up-regulation of heme oxygenase-1</article-title>. <source>European Journal of Pharmacology</source>
<volume>587</volume>: <fpage>302</fpage>&#x02013;<lpage>308</lpage>.<pub-id pub-id-type="pmid">18420187</pub-id></mixed-citation></ref><ref id="pone.0087234-Uchiyama1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Uchiyama</surname><given-names>Y</given-names></name>, <name><surname>Tagami</surname><given-names>J</given-names></name>, <name><surname>Kamisuki</surname><given-names>S</given-names></name>, <name><surname>Kasai</surname><given-names>N</given-names></name>, <name><surname>Oshige</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Selective inhibitors of terminal deoxyribonucleotidyltransferase (TdT): baicalin and genistin</article-title>. <source>Biochimica et Biophysica Acta</source>
<volume>1725</volume>: <fpage>298</fpage>&#x02013;<lpage>304</lpage>.<pub-id pub-id-type="pmid">16099107</pub-id></mixed-citation></ref><ref id="pone.0087234-Wolniak1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Wolniak</surname><given-names>M</given-names></name>, <name><surname>Oszmianski</surname><given-names>J</given-names></name>, <name><surname>Wawer</surname><given-names>I</given-names></name> (<year>2008</year>) <article-title>Solid-state NMR studies and DFT calculations of flavonoids: baicalein, baicalin and wogonoside</article-title>. <source>Magnetic Resonance in Chemistry</source>
<volume>46</volume>: <fpage>215</fpage>&#x02013;<lpage>225</lpage>.<pub-id pub-id-type="pmid">18098151</pub-id></mixed-citation></ref><ref id="pone.0087234-Wright1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Wright</surname><given-names>JD</given-names></name>, <name><surname>Boudinot</surname><given-names>FD</given-names></name>, <name><surname>Ujhelyi</surname><given-names>MR</given-names></name> (<year>1996</year>) <article-title>Measurement and analysis of unbound drug concentrations</article-title>. <source>Clinical Pharmacokinetics</source>
<volume>30</volume>: <fpage>445</fpage>&#x02013;<lpage>462</lpage>.<pub-id pub-id-type="pmid">8792057</pub-id></mixed-citation></ref><ref id="pone.0087234-Liu1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Liu</surname><given-names>H</given-names></name>, <name><surname>Bao</surname><given-names>W</given-names></name>, <name><surname>Ding</surname><given-names>H</given-names></name>, <name><surname>Jang</surname><given-names>J</given-names></name>, <name><surname>Zou</surname><given-names>G</given-names></name> (<year>2010</year>) <article-title>Binding modes of flavones to human serum albumin: insights from experimental and computational studies</article-title>. <source>The Journal of Physical Chemistry B</source>
<volume>114</volume>: <fpage>12938</fpage>&#x02013;<lpage>12947</lpage>.<pub-id pub-id-type="pmid">20845951</pub-id></mixed-citation></ref><ref id="pone.0087234-Li2"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>Q</given-names></name>, <name><surname>Yao</surname><given-names>X</given-names></name> (<year>2010</year>) <article-title>Induction of CYP3A4 and MDR1 gene expression by baicalin, baicalein, chlorogenic acid, and ginsenoside Rf through constitutive androstane receptor- and pregnane X receptor-mediated pathways</article-title>. <source>European Journal of Pharmacology</source>
<volume>640</volume>: <fpage>46</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">20580705</pub-id></mixed-citation></ref><ref id="pone.0087234-Fan1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Fan</surname><given-names>L</given-names></name>, <name><surname>Wang</surname><given-names>JC</given-names></name>, <name><surname>Jiang</surname><given-names>F</given-names></name>, <name><surname>Tan</surname><given-names>ZR</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation</article-title>. <source>European Journal of Clinical Pharmacology</source>
<volume>65</volume>: <fpage>403</fpage>&#x02013;<lpage>409</lpage>.<pub-id pub-id-type="pmid">19066872</pub-id></mixed-citation></ref><ref id="pone.0087234-Tian1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Tian</surname><given-names>X</given-names></name>, <name><surname>Cheng</surname><given-names>ZY</given-names></name>, <name><surname>He</surname><given-names>J</given-names></name>, <name><surname>Jia</surname><given-names>LJ</given-names></name>, <name><surname>Qiao</surname><given-names>HL</given-names></name> (<year>2013</year>) <article-title>Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats</article-title>. <source>Chemico-Biological Interactions</source>
<volume>203</volume>: <fpage>522</fpage>&#x02013;<lpage>529</lpage>.<pub-id pub-id-type="pmid">23458730</pub-id></mixed-citation></ref><ref id="pone.0087234-Tian2"><label>22</label><mixed-citation publication-type="other">Tian X, Cheng ZY, Jin H, Gao J, Qiao HL (2013) Inhibitory effects of baicalin on the expression and activity of CYP3A induce the pharmacokinetic changes of midazolam in rats. Evidence-Based Complementary and Alternative Medicine 2013, http: //dx.doi.org/10.1155/2013/179643.</mixed-citation></ref><ref id="pone.0087234-Gao2"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Gao</surname><given-names>N</given-names></name>, <name><surname>Zou</surname><given-names>D</given-names></name>, <name><surname>Qiao</surname><given-names>HL</given-names></name> (<year>2013</year>) <article-title>Concentration-dependent inhibitory effect of Baicalin on the plasma protein binding and metabolism of chlorzoxazone, a CYP2E1 probe substrate, in rats <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>. <source>PloS One</source>
<volume>8</volume>: <fpage>e53038</fpage>.<pub-id pub-id-type="pmid">23301016</pub-id></mixed-citation></ref><ref id="pone.0087234-Lamba1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Lamba</surname><given-names>JK</given-names></name>, <name><surname>Lin</surname><given-names>YS</given-names></name>, <name><surname>Schuetz</surname><given-names>EG</given-names></name>, <name><surname>Thummel</surname><given-names>KE</given-names></name> (<year>2012</year>) <article-title>Genetic contribution to variable human CYP3A-mediated metabolism</article-title>. <source>Advanced Drug Delivery Reviews</source>
<volume>54</volume>: <fpage>1271</fpage>&#x02013;<lpage>1294</lpage>.</mixed-citation></ref><ref id="pone.0087234-Kenworthy1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Kenworthy</surname><given-names>KE</given-names></name>, <name><surname>Bloomer</surname><given-names>JC</given-names></name>, <name><surname>Clarke</surname><given-names>SE</given-names></name>, <name><surname>Houston</surname><given-names>JB</given-names></name> (<year>1999</year>) <article-title>CYP3A4 drug interactions: correlation of 10 <italic>in vitro</italic> probe substrates</article-title>. <source>British Journal of Clinical Pharmacology</source>
<volume>48</volume>: <fpage>716</fpage>&#x02013;<lpage>727</lpage>.<pub-id pub-id-type="pmid">10594474</pub-id></mixed-citation></ref><ref id="pone.0087234-Zamuner2"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Zamuner</surname><given-names>S</given-names></name>, <name><surname>Johnson</surname><given-names>BM</given-names></name>, <name><surname>Pagliarusco</surname><given-names>S</given-names></name>, <name><surname>Fina</surname><given-names>P</given-names></name>, <name><surname>Peroni</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine</article-title>. <source>British Journal of Clinical Pharmacology</source>
<volume>70</volume>: <fpage>537</fpage>&#x02013;<lpage>546</lpage>.<pub-id pub-id-type="pmid">20840445</pub-id></mixed-citation></ref><ref id="pone.0087234-Hoch1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Hoch</surname><given-names>M</given-names></name>, <name><surname>Hoever</surname><given-names>P</given-names></name>, <name><surname>Alessi</surname><given-names>F</given-names></name>, <name><surname>Theodor</surname><given-names>R</given-names></name>, <name><surname>Dingemanse</surname><given-names>J</given-names></name> (<year>2013</year>) <article-title>Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects</article-title>. <source>European Journal of Clinical Pharmacology</source>
<volume>69</volume>: <fpage>523</fpage>&#x02013;<lpage>532</lpage>.<pub-id pub-id-type="pmid">22990330</pub-id></mixed-citation></ref><ref id="pone.0087234-Wang1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Zou</surname><given-names>MJ</given-names></name>, <name><surname>Zhao</surname><given-names>N</given-names></name>, <name><surname>Ren</surname><given-names>JG</given-names></name>, <name><surname>Zhou</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Effect of diallyl trisulfide on the pharmacokinetics of nifedipine in rats</article-title>. <source>Journal of Food Science</source>
<volume>76</volume>: <fpage>T30</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">21535728</pub-id></mixed-citation></ref><ref id="pone.0087234-GonzalezPerez1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Gonzalez-Perez</surname><given-names>V</given-names></name>, <name><surname>Connolly</surname><given-names>EA</given-names></name>, <name><surname>Bridges</surname><given-names>AS</given-names></name>, <name><surname>Wienkers</surname><given-names>LC</given-names></name>, <name><surname>Paine</surname><given-names>MF</given-names></name> (<year>2012</year>) <article-title>Impact of organic solvents on cytochrome P450 probe reactions: filling the gap with (S)-Warfarin and midazolam hydroxylation</article-title>. <source>Drug Metabolism and Disposition</source>
<volume>40</volume>: <fpage>2136</fpage>&#x02013;<lpage>2142</lpage>.<pub-id pub-id-type="pmid">22896727</pub-id></mixed-citation></ref><ref id="pone.0087234-Foti1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Foti</surname><given-names>RS</given-names></name>, <name><surname>Rock</surname><given-names>DA</given-names></name>, <name><surname>Wienkers</surname><given-names>LC</given-names></name>, <name><surname>Wahlstrom</surname><given-names>JL</given-names></name> (<year>2010</year>) <article-title>Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using <italic>in vitro</italic> data and <italic>in vivo</italic> simulation</article-title>. <source>Drug Metabolism and Disposition</source>
<volume>38</volume>: <fpage>981</fpage>&#x02013;<lpage>987</lpage>.<pub-id pub-id-type="pmid">20203109</pub-id></mixed-citation></ref><ref id="pone.0087234-Reilly1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Reilly</surname><given-names>PE</given-names></name>, <name><surname>Mason</surname><given-names>SR</given-names></name>, <name><surname>Read</surname><given-names>MA</given-names></name> (<year>1999</year>) <article-title>Human, rat and crocodile liver microsomal monooxygenase activities measured using diazepam and nifedipine: effects of CYP3A inhibitors and relationship to immunochemically detected CYP3A apoprotein</article-title>. <source>Comparative Biochemistry and Physiology Part C</source>
<volume>122</volume>: <fpage>197</fpage>&#x02013;<lpage>204</lpage>.</mixed-citation></ref><ref id="pone.0087234-Lee1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Lee</surname><given-names>KJ</given-names></name>, <name><surname>Park</surname><given-names>HJ</given-names></name>, <name><surname>Shin</surname><given-names>YH</given-names></name>, <name><surname>Lee</surname><given-names>CH</given-names></name> (<year>2004</year>) <article-title>Effect of glycyrrhizic acid on protein binding of diltiazem, verapamil, and nifedipine</article-title>. <source>Archives of Pharmacal Research</source>
<volume>27</volume>: <fpage>978</fpage>&#x02013;<lpage>983</lpage>.<pub-id pub-id-type="pmid">15473671</pub-id></mixed-citation></ref><ref id="pone.0087234-Akabane1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Akabane</surname><given-names>T</given-names></name>, <name><surname>Tabata</surname><given-names>K</given-names></name>, <name><surname>Kadono</surname><given-names>K</given-names></name>, <name><surname>Sakuda</surname><given-names>S</given-names></name>, <name><surname>Terashita</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>A comparison of pharmacokinetics between humans and monkeys</article-title>. <source>Drug Metabolism and Disposition</source>
<volume>38</volume>: <fpage>308</fpage>&#x02013;<lpage>316</lpage>.<pub-id pub-id-type="pmid">19910513</pub-id></mixed-citation></ref><ref id="pone.0087234-Poor1"><label>34</label><mixed-citation publication-type="other">Poor M, Kunsagi-Mate S, Czibulya Z, Li Y, Peles-Lemli B, <etal>et al</etal>.. (2012) Fluorescence spectroscopic investigation of competitive interactions between ochratoxin A and 13 drug molecules for binding to human serum albumin. Luminescence: In press.</mixed-citation></ref><ref id="pone.0087234-Mohri1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Mohri</surname><given-names>K</given-names></name>, <name><surname>Uesawa</surname><given-names>Y</given-names></name>, <name><surname>Sagawa</surname><given-names>K</given-names></name> (<year>2000</year>) <article-title>Effects of long-term grapefruit juice ingestion on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit juice</article-title>. <source>Drug Metabolism and Disposition</source>
<volume>28</volume>: <fpage>482</fpage>&#x02013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">10725318</pub-id></mixed-citation></ref><ref id="pone.0087234-Guo1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Guo</surname><given-names>Y</given-names></name>, <name><surname>Dai</surname><given-names>J</given-names></name>, <name><surname>Qian</surname><given-names>G</given-names></name>, <name><surname>Guo</surname><given-names>N</given-names></name>, <name><surname>Ma</surname><given-names>Z</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Determination of nifedipine in human plasma and its use in bioequivalence study</article-title>. <source>International Journal of Pharmaceutics</source>
<volume>341</volume>: <fpage>91</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">17507190</pub-id></mixed-citation></ref><ref id="pone.0087234-Zeng1"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Zeng</surname><given-names>MF</given-names></name>, <name><surname>Pan</surname><given-names>LM</given-names></name>, <name><surname>Zhu</surname><given-names>HX</given-names></name>, <name><surname>Zhang</surname><given-names>QC</given-names></name>, <name><surname>Guo</surname><given-names>LW</given-names></name> (<year>2010</year>) <article-title>Comparative pharmacokinetics of baicalin in plasma after oral administration of Huang-Lian-Jie-Du-Tang or pure baicalin in MCAO and sham-operated rats</article-title>. <source>Fitoterapia</source>
<volume>81</volume>: <fpage>490</fpage>&#x02013;<lpage>496</lpage>.<pub-id pub-id-type="pmid">20093170</pub-id></mixed-citation></ref><ref id="pone.0087234-Litterst1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Litterst</surname><given-names>CL</given-names></name>, <name><surname>Mimnaugh</surname><given-names>EG</given-names></name>, <name><surname>Reagan</surname><given-names>RL</given-names></name>, <name><surname>Gram</surname><given-names>TE</given-names></name> (<year>1975</year>) <article-title>Drug metabolism by microsomes from extrahepatic organs of rat and rabbit prepared by calcium aggregation</article-title>. <source>Life Sciences</source>
<volume>17</volume>: <fpage>813</fpage>&#x02013;<lpage>818</lpage>.<pub-id pub-id-type="pmid">813079</pub-id></mixed-citation></ref><ref id="pone.0087234-SchmiedlinRen1"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Schmiedlin-Ren</surname><given-names>P</given-names></name>, <name><surname>Thummel</surname><given-names>KE</given-names></name>, <name><surname>Fisher</surname><given-names>JM</given-names></name>, <name><surname>Paine</surname><given-names>MF</given-names></name>, <name><surname>Lown</surname><given-names>KS</given-names></name>, <etal>et al</etal> (<year>1997</year>) <article-title>Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha, 25-dihydroxyvitamin D3</article-title>. <source>Molecular pharmacology</source>
<volume>51</volume>: <fpage>741</fpage>&#x02013;<lpage>754</lpage>.<pub-id pub-id-type="pmid">9145912</pub-id></mixed-citation></ref><ref id="pone.0087234-Kim1"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Kim</surname><given-names>RB</given-names></name>, <name><surname>Wandel</surname><given-names>C</given-names></name>, <name><surname>Leake</surname><given-names>B</given-names></name>, <name><surname>Cvetkovic</surname><given-names>M</given-names></name>, <name><surname>Fromm</surname><given-names>MF</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein</article-title>. <source>Pharmaceutical Research</source>
<volume>16</volume>: <fpage>408</fpage>&#x02013;<lpage>414</lpage>.<pub-id pub-id-type="pmid">10213372</pub-id></mixed-citation></ref><ref id="pone.0087234-Buur1"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Buur</surname><given-names>JL</given-names></name>, <name><surname>Baynes</surname><given-names>RE</given-names></name>, <name><surname>Smith</surname><given-names>GW</given-names></name>, <name><surname>Riviere</surname><given-names>JE</given-names></name> (<year>2009</year>) <article-title>A physiologically based pharmacokinetic model linking plasma protein binding interactions with drug disposition</article-title>. <source>Research in Veterinary Science</source>
<volume>86</volume>: <fpage>293</fpage>&#x02013;<lpage>301</lpage>.<pub-id pub-id-type="pmid">18721993</pub-id></mixed-citation></ref><ref id="pone.0087234-Choi1"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Choi</surname><given-names>YH</given-names></name>, <name><surname>Lee</surname><given-names>MG</given-names></name> (<year>2012</year>) <article-title>Pharmacokinetic and pharmacodynamic interaction between nifedipine and metformin in rats: competitive inhibition for metabolism of nifedipine and metformin by each other via CYP isozymes</article-title>. <source>Xenobiotica</source>
<volume>42</volume>: <fpage>483</fpage>&#x02013;<lpage>495</lpage>.<pub-id pub-id-type="pmid">22416982</pub-id></mixed-citation></ref><ref id="pone.0087234-Lombardo1"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Lombardo</surname><given-names>F</given-names></name>, <name><surname>Obach</surname><given-names>RS</given-names></name>, <name><surname>Shalaeva</surname><given-names>MY</given-names></name>, <name><surname>Gao</surname><given-names>F</given-names></name> (<year>2002</year>) <article-title>Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data</article-title>. <source>Journal of Medicinal Chemistry</source>
<volume>45</volume>: <fpage>2867</fpage>&#x02013;<lpage>2876</lpage>.<pub-id pub-id-type="pmid">12061889</pub-id></mixed-citation></ref><ref id="pone.0087234-Soligard1"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Soligard</surname><given-names>HT</given-names></name>, <name><surname>Nilsen</surname><given-names>OG</given-names></name>, <name><surname>Bratlid</surname><given-names>D</given-names></name> (<year>2010</year>) <article-title>Displacement of bilirubin from albumin by ibuprofen <italic>in vitro</italic>
</article-title>. <source>Pediatric Research</source>
<volume>67</volume>: <fpage>614</fpage>&#x02013;<lpage>618</lpage>.<pub-id pub-id-type="pmid">20216106</pub-id></mixed-citation></ref><ref id="pone.0087234-Iwatsubo1"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Iwatsubo</surname><given-names>T</given-names></name>, <name><surname>Hirota</surname><given-names>N</given-names></name>, <name><surname>Ooie</surname><given-names>T</given-names></name>, <name><surname>Suzuki</surname><given-names>H</given-names></name>, <name><surname>Sugiyama</surname><given-names>Y</given-names></name> (<year>1996</year>) <article-title>Prediction of <italic>in</italic>
<italic>vivo</italic> drug disposition from <italic>in vitro</italic> data based on physiological pharmacokinetics</article-title>. <source>Biopharmaceutics and Drug Disposition</source>
<volume>17</volume>: <fpage>273</fpage>&#x02013;<lpage>310</lpage>.<pub-id pub-id-type="pmid">8845471</pub-id></mixed-citation></ref><ref id="pone.0087234-Renwick1"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Renwick</surname><given-names>AG</given-names></name>, <name><surname>Ahsan</surname><given-names>CH</given-names></name>, <name><surname>Challenor</surname><given-names>VF</given-names></name>, <name><surname>Daniels</surname><given-names>R</given-names></name>, <name><surname>Macklin</surname><given-names>BS</given-names></name>, <etal>et al</etal> (<year>1992</year>) <article-title>The influence of posture on the pharmacokinetics of orally administered nifedipine</article-title>. <source>British Journal of Clinical Pharmacology</source>
<volume>34</volume>: <fpage>332</fpage>&#x02013;<lpage>336</lpage>.<pub-id pub-id-type="pmid">1457267</pub-id></mixed-citation></ref><ref id="pone.0087234-Miyazaki1"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Miyazaki</surname><given-names>M</given-names></name>, <name><surname>Nakamura</surname><given-names>K</given-names></name>, <name><surname>Fujita</surname><given-names>Y</given-names></name>, <name><surname>Guengerich</surname><given-names>FP</given-names></name>, <name><surname>Horiuchi</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone</article-title>. <source>Drug Metabolism and Disposition</source>
<volume>36</volume>: <fpage>2287</fpage>&#x02013;<lpage>2291</lpage>.<pub-id pub-id-type="pmid">18669585</pub-id></mixed-citation></ref><ref id="pone.0087234-Lai1"><label>48</label><mixed-citation publication-type="journal">
<name><surname>Lai</surname><given-names>MY</given-names></name>, <name><surname>Hsiu</surname><given-names>SL</given-names></name>, <name><surname>Hou</surname><given-names>YC</given-names></name>, <name><surname>Tsai</surname><given-names>SY</given-names></name>, <name><surname>Chao</surname><given-names>PD</given-names></name> (<year>2004</year>) <article-title>Significant decrease of cyclosporine bioavailability in rats caused by a decoction of the roots of <italic>Scutellaria baicalensis</italic>
</article-title>. <source>Planta Medica</source>
<volume>70</volume>: <fpage>132</fpage>&#x02013;<lpage>137</lpage>.<pub-id pub-id-type="pmid">14994190</pub-id></mixed-citation></ref><ref id="pone.0087234-Aoki1"><label>49</label><mixed-citation publication-type="journal">
<name><surname>Aoki</surname><given-names>M</given-names></name>, <name><surname>Okudaira</surname><given-names>K</given-names></name>, <name><surname>Haga</surname><given-names>M</given-names></name>, <name><surname>Nishigaki</surname><given-names>R</given-names></name>, <name><surname>Hayashi</surname><given-names>M</given-names></name> (<year>2010</year>) <article-title>Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine</article-title>. <source>Drug Metabolism and Disposition</source>
<volume>38</volume>: <fpage>1183</fpage>&#x02013;<lpage>1188</lpage>.<pub-id pub-id-type="pmid">20371639</pub-id></mixed-citation></ref><ref id="pone.0087234-Grundy1"><label>50</label><mixed-citation publication-type="journal">
<name><surname>Grundy</surname><given-names>JS</given-names></name>, <name><surname>Eliot</surname><given-names>LA</given-names></name>, <name><surname>Foster</surname><given-names>RT</given-names></name> (<year>1997</year>) <article-title>Extrahepatic first-pass metabolism of nifedipine in the rat</article-title>. <source>Biopharmaceutics and Drug Disposition</source>
<volume>18</volume>: <fpage>509</fpage>&#x02013;<lpage>522</lpage>.<pub-id pub-id-type="pmid">9267683</pub-id></mixed-citation></ref><ref id="pone.0087234-Ito1"><label>51</label><mixed-citation publication-type="journal">
<name><surname>Ito</surname><given-names>K</given-names></name>, <name><surname>Brown</surname><given-names>HS</given-names></name>, <name><surname>Houston</surname><given-names>JB</given-names></name> (<year>2004</year>) <article-title>Database analyses for the prediction of <italic>in vivo</italic> drug-drug interactions from <italic>in vitro</italic> data</article-title>. <source>British Journal of Clinical Pharmacology</source>
<volume>57</volume>: <fpage>473</fpage>&#x02013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">15025746</pub-id></mixed-citation></ref><ref id="pone.0087234-Christensen1"><label>52</label><mixed-citation publication-type="journal">
<name><surname>Christensen</surname><given-names>H</given-names></name>, <name><surname>Baker</surname><given-names>M</given-names></name>, <name><surname>Tucker</surname><given-names>GT</given-names></name>, <name><surname>Rostami-Hodjegan</surname><given-names>A</given-names></name> (<year>2006</year>) <article-title>Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from <italic>in vitro</italic> data</article-title>. <source>Journal of Pharmaceutical Sciences</source>
<volume>95</volume>: <fpage>2778</fpage>&#x02013;<lpage>2787</lpage>.<pub-id pub-id-type="pmid">16937340</pub-id></mixed-citation></ref><ref id="pone.0087234-Lilja1"><label>53</label><mixed-citation publication-type="journal">
<name><surname>Lilja</surname><given-names>JJ</given-names></name>, <name><surname>Backman</surname><given-names>JT</given-names></name>, <name><surname>Neuvonen</surname><given-names>PJ</given-names></name> (<year>2005</year>) <article-title>Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects</article-title>. <source>British Journal of Clinical Pharmacology</source>
<volume>59</volume>: <fpage>433</fpage>&#x02013;<lpage>439</lpage>.<pub-id pub-id-type="pmid">15801938</pub-id></mixed-citation></ref><ref id="pone.0087234-MacKichan1"><label>54</label><mixed-citation publication-type="journal">
<name><surname>MacKichan</surname><given-names>JJ</given-names></name> (<year>1989</year>) <article-title>Protein binding drug displacement interactions fact or fiction?</article-title>
<source>Clin Pharmacokinet</source>
<volume>16</volume>: <fpage>65</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">2656044</pub-id></mixed-citation></ref></ref-list></back></article>